Technology development specialists connecting Canadian innovators to the Asia-Pacific market.
Asia Biotechnology Accelerator
Well provides a unique and proven model for supporting Canadian biotechnology companies in late-stage development for commercializing and selling products into Asia-Pacific markets.
Through our own experience in the technology development and licensing space, we established an innovative roadmap for success, which entails conceiving in Canada, developing overseas, and licensing worldwide. By tapping into global capabilities, we have grown to become a leader in technology development, commercialization, and licensing.
Our management team has extensive experience in navigating China’s jurisdiction for funding technology development. Our domestic offices are in Edmonton and Calgary, and we have expanded internationally with offices in Beijing, Guangzhou, and Qingdao.
We have also established key partnerships with the Chinese Academy of Sciences and the Guangdong Food and Drug Vocational College to further support and accelerate the growth of collaborative projects between Canadian companies and Chinese partners.
We aim to serve as a catalyst for commercializing your biotechnology product by providing you with the specialized expertise and networking necessary to overcome domestic challenges related to funding, development, and implementation.
Asia Biotechnology Accelerator
Well’s Asia Biotechnology Accelerator aims to develop partnerships between Canadian technology developers and Asia-Pacific biotechnology companies and regulators.
By combining the expertise of Well’s management team and its global capabilities, Canadian biotechnology companies will gain access to additional resources, including overseas investors, state-of-the-art facilities, and leading industry experts in the Asia-Pacific region.
Currently, Well is focusing on pharmaceutical products and diagnostic methods in late-stage development or that are market ready, with market potential in Asia.
Well is committed to developing strategic relationships and facilitating mutually beneficial financial transactions.
1. Identify potential Canadian biotechnology projects for placement in China
2. Well meets with Canadian biotechnology firm to learn about the technology, discuss company-specific needs, and identify commercialization bottlenecks
3. Well connects Canadian biotechnology firm to China partners through face-to-face meetings (facilitated at Well’s office in the Guangdong Food and Drug Vocational College)
4. Canadian biotechnology firm and China partners discuss collaborative opportunities, which may include funding assistance, expedition of Food and Drug Administration (FDA) approvals, or manufacturing arrangements
Well's Competitive Advantage
Well is a “one-stop shop” for Canadian technology developers looking to commercialize or sell into Asia-Pacific markets. There are many reasons why clients prefer Well’s Asia Biotechnology Accelerator:
partner with the best
Asia-Pacific partnerships have already been established and vetted for you
experienced in raising capital
Our partners know how to procure funding to support development initiatives
overcome language barriers
We help you overcome geographical, cultural, and language barriers in Asia
strategic partnerships in place
We have strong ties with the Guangdong Food and Drug Vocational College
College graduates feed directly into China FDA
College administration are previous China FDA high ranking officers
insights into china fda
Our partners know how to navigate and expedite the regulatory approvals process
Our partners have the infrastructure to manufacture products on a commercial scale
asia market roll-out
Our partners can place your commercialized product into China's health system
risk adverse process
You do not enter any contractual obligations until you have comfort with the overseas partners and agree with them on a path forward
At Well, we understand firsthand the constant struggle of being a small player challenging the status quo in a highly-regulated and established industry.
Our own technology commercialization journey began in 2006 when we developed SELEX-Asp, an innovative process for addressing Canadian oil sands problems. We were immediately faced with market entry barriers and found it difficult to secure a local partner to implement the technology in Canada.
Faced with limited domestic interest to further develop and commercialize our technology, we pursued and built partnerships with key Chinese institutions, which led to the successful commercialization of SELEX-Asp in 2009. Our technology has since been licensed to both state enterprise and private investors in China. Further, we have brought our commercialized technology back to Canada, have been successful in licensing it domestically, and are now expanding internationally.
We are confident that our proven technology roadmap, specialized expertise, and an established network in Asia will enable Canadian biotechnology companies to overcome existing challenges.
Confidence Through Experience